HomeCompareEMBT vs SBUX

EMBT vs SBUX: Dividend Comparison 2026

EMBT yields 2000000.06% · SBUX yields 2.75%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EMBT wins by $4.8792278646347776e+39M in total portfolio value
10 years
EMBT
EMBT
● Live price
2000000.06%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.8792278646347776e+39M
Annual income
$4,878,748,002,861,388,000,000,000,000,000,000,000,000,000,000.00
Full EMBT calculator →
SBUX
SBUX
● Live price
2.75%
Share price
$89.59
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$157.5K
Annual income
$65,840.13
Full SBUX calculator →

Portfolio growth — EMBT vs SBUX

📍 EMBT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEMBTSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EMBT + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EMBT pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EMBT
Annual income on $10K today (after 15% tax)
$170,000,005.10/yr
After 10yr DRIP, annual income (after tax)
$4,146,935,802,432,179,400,000,000,000,000,000,000,000,000,000.00/yr
SBUX
Annual income on $10K today (after 15% tax)
$233.40/yr
After 10yr DRIP, annual income (after tax)
$55,964.11/yr
At 15% tax rate, EMBT beats the other by $4,146,935,802,432,179,400,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EMBT + SBUX for your $10,000?

EMBT: 50%SBUX: 50%
100% SBUX50/50100% EMBT
Portfolio after 10yr
$2.4396139323173888e+39M
Annual income
$2,439,374,001,430,694,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

EMBT
No analyst data
Altman Z
-1935.4
Piotroski
1/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+16.1% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EMBT buys
0
SBUX buys
6
PoliticianChamberTickerTypeAmountDate
Shelley Moore Capito🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-28
Shelley Moore Capito🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-28
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Dan Newhouse🏢 House$SBUX▼ Sell$1,001 - $15,0002025-12-11
Ro Khanna🏢 House$SBUX▼ Sell$15,001 - $50,0002025-10-07
Ro Khanna🏢 House$SBUX▲ Buy$15,001 - $50,0002025-09-29
Ro Khanna🏢 House$SBUX▼ Sell$15,001 - $50,0002025-08-26
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEMBTSBUX
Forward yield2000000.06%2.75%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$4.8792278646347776e+39M$157.5K
Annual income after 10y$4,878,748,002,861,388,000,000,000,000,000,000,000,000,000,000.00$65,840.13
Total dividends collected$4.8791964691115763e+39M$127.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: EMBT vs SBUX ($10,000, DRIP)

YearEMBT PortfolioEMBT Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$200,010,706$200,000,006.00$11,107$407.21+$200.00MEMBT
2$3,738,731,992,770$3,738,517,981,314.42$12,512$626.87+$3738731.98MEMBT
3$65,315,068,744,949,500$65,311,068,301,717,240.00$14,366$978.69+$65315068744.94MEMBT
4$1,066,400,958,023,135,400,000$1,066,331,070,899,578,300,000.00$16,929$1,557.50+$1066400958023135.38MEMBT
5$16,272,185,237,131,282,000,000,000$16,271,044,188,106,197,000,000,000.00$20,658$2,543.80+$16272185237131282432.00MEMBT
6$232,054,281,880,765,440,000,000,000,000$232,036,870,642,561,700,000,000,000,000.00$26,406$4,302.22+$2.3205428188076545e+23MEMBT
7$3,092,799,715,549,616,000,000,000,000,000,000$3,092,551,417,468,003,600,000,000,000,000,000.00$35,877$7,622.00+$3.0927997155496157e+27MEMBT
8$38,524,114,942,504,994,000,000,000,000,000,000,000$38,520,805,646,809,356,000,000,000,000,000,000,000.00$52,741$14,352.64+$3.8524114942504996e+31MEMBT
9$448,468,947,092,778,960,000,000,000,000,000,000,000,000$448,427,726,289,790,500,000,000,000,000,000,000,000,000.00$85,676$29,243.03+$4.4846894709277894e+35MEMBT
10$4,879,227,864,634,777,500,000,000,000,000,000,000,000,000,000$4,878,748,002,861,388,000,000,000,000,000,000,000,000,000,000.00$157,513$65,840.13+$4.8792278646347776e+39MEMBT

EMBT vs SBUX: Complete Analysis 2026

EMBTStock

Ember Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company focuses on the clinical application of bone morphogenetic protein-7 (BMP-7) to develop regenerative medicines for the disease modification of osteoarthritis (OA), reversal of insulin resistance, and the inhibition and reversal of organ fibrosis in diseases, such as chronic kidney disease (CKD) and Alport's syndrome, as well as metabolic diseases, including obesity and type 2 diabetes. Its lead BMP-7 product candidates include MT-006, which has completed Phase 2a clinical trial for targeting OA; MT-007 that has completed Preclinical trial for CKD and Alport syndrome; MT-008, a Preclinical trial completed candidate for Alport syndrome; and MT-009, a Preclinical trial completed candidate for metabolic disease. The company also holds approximately 450 patents covering BMP-7 and its related family of BMPs, variants, novel formulations, delivery technologies, associated clinical data, and manufactured material with current good manufacturing practice. Ember Therapeutics, Inc. was founded in 2010 and is headquartered in New York, New York.

Full EMBT Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this EMBT vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EMBT vs SCHDEMBT vs JEPIEMBT vs OEMBT vs KOEMBT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.